CRA_10433

CRA_10433 is an experimental small molecule inhibitor of **cyclin-dependent kinase 2 (CDK2)**, originally developed by **Celera Genomics**. A member of the pyridazinone chemical class, the compound functions as a competitive antagonist at the ATP-binding site of CDK2, a key regulator of the eukaryotic cell cycle. CRA_10433 has been extensively characterized in structural biology research, notably through its co-crystallization with human CDK2 (as seen in PDB entry 1OIU), which helped define the structural requirements for selective kinase inhibition. Although it served as a potent lead in preclinical oncology research, the compound did not advance into clinical trials and is currently utilized primarily as a research tool or reference ligand in computational drug design and biochemical assays.

Other names

2-butyl-6-(4-methoxyphenyl)-5-(pyridin-4-yl)pyridazin-3(2H)-one2-butyl-6-(4-methoxyphenyl)-5-pyridin-4-yl-2H-pyridazin-3-one